Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
Immuneering 宣佈在 IMM-6-415 的 1/2a 期試驗中首次爲患者服用劑量，用於治療帶有 RAF 或 RAS 突變的晚期實體瘤
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
Immuneering 宣佈在 IMM-6-415 的 1/2a 期試驗中首次爲患者服用劑量，用於治療帶有 RAF 或 RAS 突變的晚期實體瘤
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。